Evidence map›Paper›PMID 40146324›Full record

ArticleMedical oncology (Northwood, London, England)2025

Enhancing KRAS G12D inhibitor sensitivity in pancreatic cancer through SHP2/PI3K pathway.

Man-Wei Hao, Tian-Xing Zhang, Dan Dong, Xin Zhou, Haicheng Gao

Abstract read
PubMed Publisher
In one paragraph

Article in Medical oncology (Northwood, London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Man-Wei Hao *School of Pharmaceutical Sciences, Jilin University, Changchun, 130021, China.
Tian-Xing Zhang *School of Pharmaceutical Sciences, Jilin University, Changchun, 130021, China.
Dan DongGynaecology and Obstetrics Center, The First Hospital of Jilin University, Changchun, 130021, China.
Xin ZhouCancer Research Institute of Jilin University, The First Hospital of Jilin University, Changchun, 130021, China.
Haicheng GaoSchool of Pharmaceutical Sciences, Jilin University, Changchun, 130021, China. gaohc@jlu.edu.cn.

Funding

the Department of Science and Technology of Jilin Province 20210401076YYthe National Natural Science Foundation of China 82002962the Norman Bethune Program 2023B06
6 · The paper itself

Abstract

Pancreatic cancer with the KRAS G12D mutation, found in 40% of cases, is challenging to treat. MRTX1133, a non-covalent KRAS G12D inhibitor, shows therapeutic promise but faces resistance issues. Our study combines MRTX1133 with the SHP2 inhibitor SHP099 or PI3K inhibitor Buparlisib, showing synergistic inhibition of pancreatic cancer cell growth and enhanced apoptosis. These combination therapies could improve clinical outcomes for patients with KRAS G12D  mutation in pancreatic cancer.

Indexed as

Pancreatic NeoplasmsProtein Tyrosine Phosphatase, Non-Receptor Type 11Proto-Oncogene Proteins p21(ras)AminopyridinesAnimalsAntineoplastic Combined Chemotherapy ProtocolsApoptosisCell Line, TumorCell ProliferationDrug Resistance, NeoplasmDrug SynergismHeterocyclic Compounds, 3-RingHumansIndazolesMorpholinesMutation2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidineAminopyridinesHeterocyclic Compounds, 3-RingIndazolesKRAS protein, humanMorpholinesPhosphatidylinositol 3-KinasesPhosphoinositide-3 Kinase InhibitorsPiperidinesProtein Tyrosine Phosphatase, Non-Receptor Type 11Proto-Oncogene Proteins p21(ras)PTPN11 protein, humanPyrimidinesSHP099SulfonamidesBuparlisibDrug resistanceKRAS mutationMRTX1133Pancreatic cancerSHP099

Identifiers

PMID40146324

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.